Non-oral therapies burden PAH patients

Aug 4, 2025

1 min read

This study looked at the challenges and impacts of non-oral treatments for pulmonary arterial hypertension (PAH), beyond those caused by PAH itself. They found that people taking oral-only therapies and people taking non-oral therapy had similar health, but those taking non-oral therapy had worse quality of life, as non-oral therapy interfered with daily activities.

Read the Therapeutic Advances in Respiratory Disease article

Recent Posts

First two patients enrolled in a clinical trial to treat Group 2 PH

A press release announced that the first two patients have enrolled in a trial of a treatment for Group 2 pulmonary hypertension (PH associated with left heart disease). The treatment procedure is min

Animal research shows miR-224 contributes to PAH

A small molecule called microRNA-224-5p (miR-224) appears to play an important role in the changes to the lung blood vessels that occur in pulmonary arterial hypertension (PAH). Researchers found that

Dual PH therapy before BPA lowers complications

Researchers found that pre-treating pulmonary hypertension (PH) patients with dual therapy before they underwent balloon pulmonary angioplasty was associated with lower complications and better clinic

Comments